Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study

Molidustat, an orally administered hypoxia‐inducible factor prolyl‐hydroxylase inhibitor, is under development for the treatment of anemia of CKD. This 24‐week, phase 3, single‐arm, multicenter study evaluated the efficacy and safety of molidustat in Japanese patients with renal anemia who were unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Nobori, Kiyoshi, Matsuda, Yoshimi, Hayashi, Yasuhiro, Hayasaki, Takanori, Yamamoto, Hiroyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291098/
https://www.ncbi.nlm.nih.gov/pubmed/33506635
http://dx.doi.org/10.1111/1744-9987.13627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291098/
https://www.ncbi.nlm.nih.gov/pubmed/33506635
http://dx.doi.org/10.1111/1744-9987.13627

Ejemplares similares